UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
SCHEDULE 13G
UNDER THE SECURITIES EXCHANGE ACT OF 1934
(Amendment No. )*
----------
Sunesis Pharmaceuticals, Inc.
--------------------------------------------------------------------------------
(Name of Issuer)
Common Stock, par value $0.0001 per share
--------------------------------------------------------------------------------
(Title of Class of Securities)
867328 50 2
--------------------------------------------------------------------------------
(CUSIP Number)
December 31, 2005
--------------------------------------------------------------------------------
(Date of Event Which Requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant to which this Schedule
is filed:
[ ] Rule 13d-1(b)
[ ] Rule 13d-1(c)
[X] Rule 13d-1(d)
*The remainder of this cover page shall be filled out for a reporting person's
initial filing on this form with respect to the subject class of securities, and
for any subsequent amendment containing information which would alter the
disclosures provided in a prior cover page.
The information required in the remainder of this cover page shall not be deemed
to be "filed" for the purpose of Section 18 of the Securities Exchange Act of
1934 (the "Act") or otherwise subject to the liabilities of that section of the
Act but shall be subject to all other provisions of the Act.
Page 1 of 8
---------------------
CUSIP NO. 867328 50 2
---------------------
--------------------------------------------------------------------------------
1 NAME(S) OF REPORTING PERSON(S)
S.S. OR I.R.S. IDENTIFICATION NO(S). OF ABOVE PERSON(S)
Biogen Idec Inc.
33-0112644
--------------------------------------------------------------------------------
2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
(a) [ ]
(b) [ ]
--------------------------------------------------------------------------------
3 SEC USE ONLY
--------------------------------------------------------------------------------
4 CITIZENSHIP OR PLACE OF ORGANIZATION
Delaware
--------------------------------------------------------------------------------
5 SOLE VOTING POWER
0
NUMBER ---------------------------------------------------------
6 SHARED VOTING POWER
OF SHARES
2,912,022
BENEFICIALLY
---------------------------------------------------------
OWNED BY 7 SOLE DISPOSITIVE POWER
EACH REPORTING 0
PERSON WITH ---------------------------------------------------------
8 SHARED DISPOSITIVE POWER
2,912,022
--------------------------------------------------------------------------------
9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
2,912,022
--------------------------------------------------------------------------------
10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
Not applicable
--------------------------------------------------------------------------------
11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9
13.6%
--------------------------------------------------------------------------------
12 TYPE OF REPORTING PERSON
CO
--------------------------------------------------------------------------------
Page 2 of 8
---------------------
CUSIP NO. 867328 50 2
---------------------
--------------------------------------------------------------------------------
1 NAME(S) OF REPORTING PERSON(S)
S.S. OR I.R.S. IDENTIFICATION NO(S). OF ABOVE PERSON(S)
Biogen Idec MA Inc.
04-3002117
--------------------------------------------------------------------------------
2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
(a) [ ]
(b) [ ]
--------------------------------------------------------------------------------
3 SEC USE ONLY
--------------------------------------------------------------------------------
4 CITIZENSHIP OR PLACE OF ORGANIZATION
Massachusetts
--------------------------------------------------------------------------------
5 SOLE VOTING POWER
0
NUMBER ---------------------------------------------------------
6 SHARED VOTING POWER
OF SHARES
2,912,022
BENEFICIALLY
---------------------------------------------------------
OWNED BY 7 SOLE DISPOSITIVE POWER
EACH REPORTING 0
PERSON WITH ---------------------------------------------------------
8 SHARED DISPOSITIVE POWER
2,912,022
--------------------------------------------------------------------------------
9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
2,912,022
--------------------------------------------------------------------------------
10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
Not applicable
--------------------------------------------------------------------------------
11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9
13.6%
--------------------------------------------------------------------------------
12 TYPE OF REPORTING PERSON
CO
--------------------------------------------------------------------------------
Page 3 of 8
Item 1(a) Name of Issuer
Sunesis Pharmaceuticals, Inc.
Item 1(b) Address of Issuer's Principal Executive Offices
341 Oyster Point Blvd.
South San Francisco, California 94080
Item 2(a) Names of Persons Filing
(i) Biogen Idec Inc.
(ii) Biogen Idec MA Inc.
Item 2(b) Address of Principal Business Office or, if none, Residence
(i) 14 Cambridge Center, Cambridge, Massachusetts 02142
(ii) 14 Cambridge Center, Cambridge, Massachusetts 02142
Item 2(c) Citizenship
(i) Delaware
(ii) Massachusetts
Item 2(d) Title of Class of Securities
Common Stock, par value $0.0001 per share
Item 2(e) CUSIP Number
867328 50 2
Item 3 If this statement is filed pursuant to Rules 13d-1(b) or
13d-2(b) or (c), check whether the person filing is a:
Not Applicable
(a) [ ] Broker or dealer registered under Section 15 of the Act;
(b) [ ] Bank as defined in section 3(a)(6) of the Act;
(c) [ ] Insurance company as defined in Section 3(a)(19) of the
Act;
(d) [ ] Investment company registered under Section 8 of the
Investment Company Act;
(e) [ ] An investment adviser in accordance with
Rule 13d-1(b)(1)(ii)(E);
Page 4 of 8
(f) [ ] An employee benefit plan or endowment fund in accordance
with Rule 13d-1(b)(1)(ii)(F);
(g) [ ] A parent holding company or control person in accordance
with Rule 13d-1(b)(1)(ii)(G);
(h) [ ] A savings associations as defined in Section 3(b) of the
Federal Deposit Insurance Act;
(i) [ ] A church plan that is excluded from the definition of an
investment company under section 3(c)(14) of the
Investment Company Act;
(j) [ ] Group, in accordance with Rule 13d-1(b)(1)(ii)(J).
Item 4 Ownership
(a) Amount Beneficially Owned:
2,912,022
Shares of Sunesis Common Stock are owned directly by Biogen
Idec MA Inc., a wholly owned subsidiary of Biogen Idec Inc.,
and indirectly by Biogen Idec Inc.
(b) Percent of Class:
13.6%.
This percentage was calculated based on disclosure in the
Issuer's Quarterly Report on Form 10-Q filed November 14,
2005, that on November 10, 1005, there were 21,460,214
shares of Common Stock outstanding.
(c) Number of shares as to which such persons have:
(i) sole power to vote or to direct the vote:
0
(ii) shared power to vote or to direct the vote:
2,912,022
(iii) sole power to dispose or to direct the disposition of:
0
(iv) shared power to dispose or to direct the disposition
of:
2,912,022
Item 5 Ownership of Five Percent or Less of a Class
Page 5 of 8
If this statement is being filed to report the fact that as of the date
hereof the reporting person has ceased to be the beneficial owner of more than
five percent of the class of securities, check the following [ ].
Not Applicable
Item 6 Ownership of More than Five Percent on Behalf of Another Person
Not Applicable
Item 7 Identification and Classification of the Subsidiary Which
Acquired the Security Being Reported on by the Parent Holding
Company
Not Applicable
Item 8 Identification and Classification of Members of the Group
Not Applicable
Item 9 Notice of Dissolution of Group
Not applicable
Item 10 Certification
Not applicable
INDEX TO EXHIBITS
Exhibit Number Exhibit
-------------- -------
99.1 Joint Filing Agreement
Page 6 of 8
Signature
After reasonable inquiry and to the best of my knowledge and belief, I
certify that the information set forth in this statement is true, complete and
correct.
Dated: February 14, 2006
BIOGEN IDEC INC.
By: /s/ Michael F. Phelps
--------------------------------
Name: Michael F. Phelps
Title: Vice President, Treasurer
BIOGEN IDEC MA INC.
By: /s/ Michael F. Phelps
--------------------------------
Name: Michael F. Phelps
Title: Vice President, Treasurer
Page 7 of 8